- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Joseph Fuhr: Biosimilars Bring on Brand-to-Brand Competition
Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses the impact that biosimilars will have on the healthcare industry.
Transcript (slightly modified)
How will biosimilars impact our healthcare industry?
One of the issues about biosimilars is that they’re taking away the monopoly of a biologic. Now, there is a lot of money that is spent in terms of biologics and in terms of research and development. So they need to get a fair return on their investment. So what we have here is the issue of allowing for innovation, which then will increase consumer welfare—people benefit from these drugs—and at the same time allow for access to consumers but also allow for innovation of new drugs that will benefit society. One of the things that we see that is different from the generic market in the biosimilar market is that many of the brand-name companies are actually getting into the biosimilar market, so we’ll see competition more like brand-to-brand than we see brand-to-generic.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
